Comparison and analytical bridging of digital PCR platforms for AAV titration

Adeno-associated virus (AAV) has emerged as the primary vector for in vivo gene therapy applications. AAV samples are measured and dosed via DNA concentration, traditionally determined by quantitative PCR (qPCR). qPCR is gradually being replaced by the more precise digital PCR method, which achieves absolute quantification of target sequences without standard curves. A precise AAV titration method is critical for the entire drug development journey, from preclinical studies, through process development and clinical dosing.

This webinar will cover:

Development of well-controlled AAV titration methods
Comparison of multiple digital PCR platforms for AAV titration
Strategies for bridging legacy qPCR methods to improved digital PCR platforms

About the speaker

Stuart Nelson, Technical Lead of Analytical Control Strategy

Eli Lilly and Company

Stuart Nelson is a Technical Lead of Analytical Control Strategy at Eli Lilly. Stuart has over a decade of industry experience in drug development for several biologic modalities. He joined Prevail Therapeutics in 2018 (acquired by Lilly in 2021), holding increasing levels of responsibility over the last 4+ years. His most recent contributions were as part of the CMC and analytical development teams, helping advance multiple gene therapy programs from pre-IND to clinical dosing.